Aclarion Launches New Jersey Network Using Nociscan Technology for Objective Low Back Pain Assessment in Legal Cases

Aclarion, Inc., a healthcare technology company specializing in chronic low back pain identification, has announced an initiative to develop a statewide network of providers in New Jersey. This network will utilize Aclarion's Nociscan technology to evaluate chronic low back pain in personal injury and workers compensation cases, potentially transforming how these cases are assessed and treated. The program, led by Dr. Justin Kubeck, an orthopedic surgeon and founder of Ocean Pain and Spine in Toms River, NJ, aims to improve the objective evaluation of chronic low back pain patients within the complex personal injury and workers compensation system.

This initiative is particularly significant given the high stakes involved in such cases. In New Jersey, the average settlement for personal injury claims involving the neck and back is $918,967, while work-related accidents causing neck and back injuries have a national average settlement of $148,750. Nociscan, Aclarion's flagship product, uses Magnetic Resonance Spectroscopy (MRS) and proprietary AI algorithms to help physicians identify the location of chronic low back pain. By providing objective data on biomarkers in the lumbar disc correlated to pain and structural integrity, Nociscan offers a powerful tool for supporting appropriate treatment pathways in legal settings where objective evidence is crucial.

Dr. Kubeck emphasized the importance of this technology in the legal context: "The nature of these claims mandates an objective and definitive diagnosis, knowing that the diagnosis may well be challenged in a legal setting. The use of Nociscan can be a powerful objective measurement tool to provide a strong case for supporting an appropriate treatment pathway." The initiative has broader implications beyond New Jersey. Ryan Bond, Chief Strategy Officer of Aclarion, stated that once established in New Jersey, the company plans to target other markets throughout the United States to replicate the success. This expansion could significantly impact how chronic low back pain is evaluated and treated in personal injury and workers compensation cases nationwide.

Aclarion's Nociscan technology works by receiving MRS data from an MRI machine for each lumbar disc being evaluated. Proprietary signal processing techniques then extract and quantify chemical biomarkers associated with disc pain. This data is entered into algorithms to indicate if a disc may be a source of pain, providing critical insights when used alongside other diagnostic tools. The potential impact of this initiative on the healthcare and legal sectors is substantial. By providing more objective data in cases that often rely heavily on subjective pain assessments, Nociscan could help streamline the evaluation process, potentially leading to more accurate diagnoses, appropriate treatments, and fair compensation for injured parties.

For the medical community, this technology offers a new tool in the challenging field of chronic pain management. For the legal system, it provides a more robust basis for decision-making in personal injury and workers compensation cases. And for patients, it could mean faster, more accurate diagnoses and more effective treatment plans. As Aclarion moves forward with this initiative, it will be crucial to monitor its implementation and effectiveness. If successful, this approach could set a new standard for evaluating chronic low back pain in legal and medical contexts, potentially benefiting patients, healthcare providers, and the legal system alike.